|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Current: | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Restricted cash | |||||||||||||
| Accounts receivable, net | |||||||||||||
| Prepaids, deposits and other receivables | |||||||||||||
| Other receivables | |||||||||||||
| Inventories, net | |||||||||||||
| Total current assets | |||||||||||||
| Investment – Cansativa | |||||||||||||
| Cansativa | |||||||||||||
| Total investment – Cansativa | |||||||||||||
| Property, plant and equipment, net of accumulated depreciation of $8,793 and $7,120 for the years ended December 31, 2023 and 2022, respectively | |||||||||||||
| Land held for sale | |||||||||||||
| Intangible assets, net | |||||||||||||
| Goodwill | |||||||||||||
| Operating lease right-of-use assets, net | |||||||||||||
| Other non-current assets | |||||||||||||
| Total Assets | |||||||||||||
| Liabilities and Stockholders' equity | |||||||||||||
| Liabilities and Shareholders' Equity | |||||||||||||
| Current: | |||||||||||||
| Accounts payable | |||||||||||||
| Accrued expense and other current liabilities | |||||||||||||
| Convertible note due 2024, current portion | |||||||||||||
| Convertible note due 2024 | |||||||||||||
| Total convertible note due 2024, current portion | |||||||||||||
| Loans and borrowings, current portion | |||||||||||||
| Warrant liability | |||||||||||||
| Operating lease liabilities, current portion | |||||||||||||
| Deferred revenue | |||||||||||||
| Total current liabilities | |||||||||||||
| Convertible notes | |||||||||||||
| Convertible notes | |||||||||||||
| Convertible note due 2024 | |||||||||||||
| Convertible notes due 2022 | |||||||||||||
| Total convertible notes | |||||||||||||
| Loans and borrowings, net of current portion | |||||||||||||
| Loans and borrowings | |||||||||||||
| Deferred revenue | |||||||||||||
| Operating lease liabilities — long-term | |||||||||||||
| Deferred tax liabilities | |||||||||||||
| Other long-term liabilities | |||||||||||||
| Total Liabilities | |||||||||||||
| Shareholders’ equity | |||||||||||||
| Preferred shares, without par value, unlimited shares authorized, nil shares issued and outstanding for each of December 31, 2023 and 2022 | |||||||||||||
| Common shares, without par value, unlimited shares authorized: 1,727,698 and 1,454,559 shares issued and outstanding as of December 31, 2023 and 2022, respectively | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total shareholders' equity | |||||||||||||
| Total liabilities and shareholders' equity | |||||||||||||
Loading...
